FY24 revenue consensus $217.06M. The Company projects full year 2024 gross margin to be approximately 61%. This compares to previous guidance of approximately 59%. The Company projects full year 2024 total operating expense of approximately $231.5 million, which is unchanged from previously issued guidance. The Company projects full year 2024 Adjusted EBITDA loss to be ($60.0) million. This compares to previous guidance of ($67.5) million
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Is PRCT a Buy, Before Earnings?
- Closing Bell Movers: DocuSign up over 5% after entering S&P MidCap 400
- Procept BioRobotics announces FDA approval to initiate Aquablation therapy study
- Procept BioRobotics price target raised to $99 from $75 at TD Cowen
- BTIG medical technology analyst holds an analyst/industry conference call